Loading...
Please wait, while we are loading the content...
or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
| Content Provider | CiteSeerX |
|---|---|
| Author | Sims, Robert B. |
| Abstract | licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. Received: 2011.04.29; Accepted: 2011.06.03; Published: 2011.06.15 Sipuleucel T is an autologous cellular immunotherapy designed to stimulate an immune response in men diagnosed with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Sipuleucel T improves overall survival and provides an additional treatment option for this patient population. Key words: sipuleucel-T, metastatic castrate resistant prostate cancer (mCRPC) Prostate cancer is a major health concern. It is the second leading cause of death from cancer among males in most western countries. Localized prostate cancer may be cured with surgery or radiation therapy, but unfortunately the disease recurs in up to 30% of patients. Disease recurrence is often noted by a progressive rise in serum prostate specific antigen |
| File Format | |
| Access Restriction | Open |
| Subject Keyword | Disease Recurs Noncommercial Use Progressive Rise Second Leading Cause Autologous Cellular Immunotherapy Immune Response Patient Population Additional Treatment Option Metastatic Castrate Resistant Prostate Cancer Major Health Concern Western Country Radiation Therapy Disease Recurrence Localized Prostate Cancer Overall Survival Hormone Refractory Serum Prostate Specific Antigen Prostate Cancer Symptomatic Metastatic Castrate Resistant |
| Content Type | Text |
| Resource Type | Article |